Original document(29 pages) Authorized document(28 pages) 中文版
    The invention relates to a N-aryl substituted-1H pyrrole derivative or its salt having cardiovascular activity represented by formula (I), which has activity angiotensin II (AII) acceptor antagonism and can be applied in treating cardiovascular diseases e.g. hypertension, hyperemia heart failure, myocardium pachismus, vasospasm and other diseases or symptoms treated through blockading AII acceptor.
Application Number
申请号
200310106428 Application Date
申请日
2003.11.26
Title 名称 N-aryl substituted-1H-pyrrole derivative possessing cardiovascular activity
Publication Number
公开号
1544418 Publication Date
公开日
2004.11.10
Approval Pub. Date 2006.05.24 Granted Pub. Date 2006.05.24
International Classification 分类号 C07D207/30,C07D207/412,C07D403/06,C07D471/04,A61K31/40,A61P9/12,A61P9/04,A61P7/10
Applicant(s) Name
申请人
China Pharmaceutical University
Address 地址 210009
Inventor(s) Name 发明人 Wu Xiaoming, Xu Jinyi
Attorney & Agent 代理人 zhou hebeng li zhongbeng

  
Polyglutaminic acid or sodium polyglutamate taxinine A ester compound and use thereof
Water soluble cephalotaxin phosphorus poly aminoacid ester or its salt, pharmaceutical compositions contg. same, and pharmaceutical use thereof
Water-soluble powder injection of ormosin VI and its preparing process and application
Polygonum tataricum tea and producing method
Threading mechanism of sewing machine
Traditional Chinese medicine for treating and preventing high blood pressure and its preparation technology
Stable pharmaceutical composition containing calcium blocker
Method for preparing cooked nourished wheat and rice
Isochromanone 4 derivate, its preparation process and therapeutic use
Use of isochromanone 4 derivative
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.